44 results
8-K
EX-10.2
RVNC
Revance Therapeutics Inc
28 Feb 24
Provides Corporate Update
4:07pm
) existence of any business discussions, negotiations or agreements between the parties; and (e) any information regarding the skills and compensation
PRE 14A
RVNC
Revance Therapeutics Inc
12 Mar 21
Preliminary proxy
4:13pm
or death.
We believe that our continuing directors as a group have an appropriate mix of qualifications, attributes, skills and experience … . The following table and graphics provide summary information about the qualifications, attributes, skills and experience of our continuing directors.
Table
8-K
EX-99.2
27c3setwhs7k vkdxc6
22 Feb 21
Revance Reports Fourth Quarter and Full Year 2020 Financial Results
4:06pm
8-K
EX-99.1
hn1z88 2w
22 Feb 21
Revance Reports Fourth Quarter and Full Year 2020 Financial Results
4:06pm
424B3
etsq5sf
24 Jun 20
Prospectus supplement
5:18pm
S-4/A
g05nllkfc1kk
23 Jun 20
Registration of securities issued in business combination transactions (amended)
6:09am
S-4
8wraftp
9 Jun 20
Registration of securities issued in business combination transactions
9:48pm
8-K
EX-99.2
w31ca446a6yb4
10 Feb 20
Revance Announces Proposed Private Offering of
4:01pm